Home›Trial›NCT05046613
NCT05046613RECRUITING

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Study Summary

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Conditions
Migraine
Interventions / Drugs
RimegepantNot taking Rimegepant
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F33/100
Study Details
Enrollment780 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.189889+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 780 participants
Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company F (33/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.